Organization
Albert B. Sabin Vaccine Institute
3 clinical trials
1 abstract
Clinical trial
Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy AdultsStatus: Completed, Estimated PCD: 2023-07-28
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy AdultsStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Abstract
Using machine learning-based boosting algorithm to predict hepatotoxicity after local therapy and association with survival in patients undergoing liver directed therapy.Org: Montefiore Medical Center, Albert Einstein College of Medicine, Albert B. Sabin Vaccine Institute, Albert Einstein College of Medicine - Montefiore Medical Center,